Skip to main content

Obesity drug industry could be worth $200 billion within the decade, says Barclays, as market valuations grow

The burgeoning weight-loss drug industry could be worth as much as $200 billion within the next decade, according to Barclays bank.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.